[Second-line treatment of advanced renal cell carcinoma after first-line targeted therapy].
Cytokines were the only drugs proven to be effective for advanced renal cell carcinoma(RCC). Introducing the targeted drugs prolonged patients' survival. However, limited high-quality evidence is now available for second-line treatment. Everolimus is effective for patients who have experienced progression of disease after sunitinib and/or sorafenib. Further prospective study including the sequencing of targeted drugs is warranted to develop better treatment strategies.